----item----
version: 1
id: {7E3AF0BA-DED9-40D8-AD54-E6E352AF4043}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/03/25/FDA OKs Novartis oral iron chelator Jadenu
parent: {CE0B93D3-20EA-4DFE-BC95-04ADDD6DB633}
name: FDA OKs Novartis oral iron chelator Jadenu
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 6e2c1b7a-6a02-459f-a606-63dab43baf19

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 44

FDA OK's Novartis' oral iron chelator Jadenu
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 42

FDA OKs Novartis oral iron chelator Jadenu
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1583

<p>Novartis won the FDA's approval to market Jadenu (deferasirox) as a treatment for chronic iron overload, a life-threatening cumulative toxicity that results from blood transfusions required to treat sickle cell disease, myelodysplastic syndromes, thalassemia and other conditions. </p><p>Chronic iron overload also can occur in patients with non-transfusion-dependent thalassemia syndromes (NTDT) due to increased iron absorption in the stomach and intestines. </p><p>If left untreated, chronic iron overload can damage the liver and heart.</p><p>Novartis said Jadenu is a new once-daily formulation of Exjade (deferasirox), which was initially approved in 2005.</p><p>Jadenu simplifies daily treatment administration for patients with chronic iron overload, the company said.</p><p>Specifically, Jadenu is approved as a treatment for chronic iron overload due to blood transfusions in patients two years or older and for chronic iron overload in NTDT in patients 10 years or older. </p><p>Novartis said Jadenu is the only once-daily oral iron chelator that can be swallowed whole. </p><p><b>Related articles</b></p><p><a href="http://www.scripintelligence.com/policyregulation/Novartis-Exjade-OKd-in-US-for-non-transfusion-dependent-thalassemia-339341" target="_new">Novartis Exjade OK'd in US for non-transfusion-dependent thalassemia</a></p><p><a href="http://www.scripintelligence.com/policyregulation/ApoPharma-gains-accelerated-approval-for-chelation-therapy-322512" target="_new">ApoPharma gains accelerated approval for chelation therapy</a></p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 288

<p>Novartis won the FDA's approval to market Jadenu (deferasirox) as a treatment for chronic iron overload, a life-threatening cumulative toxicity that results from blood transfusions required to treat sickle cell disease, myelodysplastic syndromes, thalassemia and other conditions. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 42

FDA OKs Novartis oral iron chelator Jadenu
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150325T174028
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150325T174028
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150325T174028
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028287
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 44

FDA OK's Novartis' oral iron chelator Jadenu
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357492
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042323Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

6e2c1b7a-6a02-459f-a606-63dab43baf19
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042323Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
